Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ADAG
- Price
- 1.53
- Stock movement up
- +0.05 (3.38%)
- Company name
- Adagene Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 67.73M
- Ent value
- 16.25M
- Price/Sales
- 166.07
- Price/Book
- 1.20
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -48.83%
- 3 year return
- -25.43%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ADAG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 166.07 |
| Price to Book | 1.20 |
| EV to Sales | 39.85 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 44.27M |
| EPS (TTM) | -0.75 |
| FCF per share (TTM) | -0.45 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 407.87K |
| Gross profit (TTM) | -17.59K |
| Operating income (TTM) | -36.82M |
| Net income (TTM) | -32.94M |
| EPS (TTM) | -0.75 |
| EPS (1y forward) | -0.69 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -4.31% |
| Operating margin (TTM) | -9026.88% |
| Profit margin (TTM) | -8075.15% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 95.67M |
| Net receivables | 31.42K |
| Total current assets | 98.80M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 100.78M |
| Accounts payable | 3.37M |
| Short/Current long term debt | 20.79M |
| Total current liabilities | 39.52M |
| Total liabilities | 44.19M |
| Shareholder's equity | 56.59M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -20.06M |
| Capital expenditures (TTM) | 18.82K |
| Free cash flow (TTM) | -20.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -58.20% |
| Return on Assets | -32.68% |
| Return on Invested Capital | -45.30% |
| Cash Return on Invested Capital | -27.62% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.45 |
| Daily high | 1.55 |
| Daily low | 1.45 |
| Daily Volume | 6K |
| All-time high | 29.60 |
| 1y analyst estimate | 10.54 |
| Beta | 0.58 |
| EPS (TTM) | -0.75 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ADAG | S&P500 | |
| Current price drop from All-time high | -94.83% | -12.89% |
| Highest price drop | -96.96% | -56.47% |
| Date of highest drop | 31 Oct 2022 | 9 Mar 2009 |
| Avg drop from high | -82.89% | -11.07% |
| Avg time to new high | 525 days | 12 days |
| Max time to new high | 1047 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
67.73M
Marketcap category
Small-cap
Description
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Employees
174
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page